Delcath to Present at Canaccord Genuity 40th Annual Growth Conference
August 03 2020 - 1:48PM
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology
company focused on liver-directed treatment of rare primary and
metastatic cancers, today announced that John Purpura, interim
Chief Executive Officer, will be presenting virtually on Wednesday,
August 12, 2020 at 9 a.m. ET in Track 5 at the Canaccord Genuity
40th Annual Growth Conference. A webcast of the presentation will
be available at the following link:
http://wsw.com/webcast/canaccord42/dcth/
The Company will also be participating in
one-on-one investor meetings. To schedule a meeting, please contact
your Canaccord representative or email James@HaydenIR.com
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional
oncology company focused on the treatment of primary and metastatic
liver cancers. Our investigational product Melphalan Hydrochloride
for Injection for use with the Delcath Hepatic Delivery System
(Melphalan/HDS) – is designed to administer high-dose chemotherapy
to the liver while minimizing systemic exposure and associated side
effects. In addition to the Phase 3 FOCUS Trial, we have initiated
a global Phase 3 clinical trial for intrahepatic cholangiocarcinoma
(ICC) called The ALIGN Trial. We currently are also evaluating
other forms of metastatic liver cancers. Melphalan/HDS has
not been approved by the U.S. Food & Drug Administration (FDA)
for sale in the U.S. In Europe, our system is marketed under the
trade name Delcath CHEMOSAT® Hepatic Delivery System for
Melphalan (CHEMOSAT) and has been CE Marked and used at major
medical centers to treat a wide range of cancers of the liver.
CHEMOSAT is being marketed under an exclusive licensing agreement
with medac GmbH, a privately held multi-national pharmaceutical
company headquartered in Germany that specializes in the treatment
and diagnosis of oncological, urological and autoimmune
diseases.
Contact:
Hayden IRJames
Carbonara(646)-755-7412james@haydenir.com
Brett Maas(646) 536-7331brett@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Apr 2023 to Apr 2024